Study about Wound Healing, Evolution of Cancer and War on Cancer | Chapter 14 | Recent Developments in Medicine and Medical Research Vol. 8

 The impact of wounds on the progression and treatment of cancer is highlighted in this review. The goal of this review is to look into the process of wound healing and how it relates to cancer evolution and treatment. Proliferation and terminal differentiation (TD) of progenitor stem cells (PSCs), the progenitors of cancer stem cells, are required for wound healing (CSCs). It is not difficult to heal a wound. If the chemo-surveillance system is working properly, such as in healthy people who can keep a constant level of wound healing metabolites acting as differentiation inducers (DIs) and differentiation helper inducers (DHIs). Wounds are always properly healed without any effort on the part of the patient; all that is required is for the patient to relax and allow nature to cure the wound. Sutures and antibiotics are used as a last resort to speed up the healing process or avoid infection. The functionality of chemo-surveillance is momentarily harmed by an acute wound, which heals fast and returns to normal. Chronic wounds, such as persistent viral illnesses or long-term exposure to toxic substances, especially carcinogens, have a negative impact on chemo-surveillance functionality. Wound healing is hampered by the generation of inflammatory cytokines, which promote increased urine excretion of wound repair metabolites. It is relatively easy for PSCs to transition into CSCs if there aren't enough wound healing metabolites to stop PCSs from proliferating. To complete the change, all it takes is a single hit to silence the TET-1 enzyme, which is well within the reach of PSCs with abnormally active methylation enzymes (MEs). The activation of oncogenes or the silencing of oncogenes in CSCs can then lead to the development of faster growing cancer cells (AML). MDS and AML aren't the only ones who get cancer because their wounds don't heal properly. It's a rather typical occurrence. The war on cancer can be easily won if the combat is performed in accordance with nature's path for healing the wound, similar to the success of wound healing in healthy people without exerting any effort. As a result, using DIs and DHIs to restore chemo-surveillance functionality and anti-cachexia compounds like phenylacetylglutamine to prevent the loss of wound healing metabolites is the greatest way to win the war on cancer. The proliferation of cells with aberrant MEs, such as CSCs, PSCs, and all cancer cells, will thereafter be stopped by nature. Destruction as a method of killing cancer cells is clearly counterproductive. It causes more damage to the chemo-surveillance system's ability to inhibit the proliferation of cells with aberrant MEs. The failure of the destruction strategy to eliminate CSCs is a deciding factor in denying the destruction approach's ability to win the cancer fight.

Author(S) Details

Ming C. Liau
CDA Therapeutics, Inc, 3308 Sky Run Court, Missouri City, TX 77459, USA.

Linda Liau Baker
CDA Therapeutics, Inc, 3308 Sky Run Court, Missouri City, TX 77459, USA.

View Book:- https://stm.bookpi.org/RDMMR-V8/article/view/4573

Destabilization of Abnormal Methylation Enzymes as an Effective Therapeutic Strategy via Induction of Terminal Differentiation to Take Out Both Cancer Stem Cells and Cancer Cells | Chapter 11 | Current Aspects in Pharmaceutical Research and Development Vol. 2

 The goal of this research was to discover cancer medications that would kill both cancer stem cells (CSCs) and cancer cells, with a focus on CSCs because they were preventing traditional cancer treatments from working. The interaction of methylation enzymes with telomerase is a specific cancer cell defect. This anomaly keeps methylation enzymes extremely stable and active, preventing the cells from hypomethylating their nucleic acids, which is required for Terminal Differentiation (TD). To allow TD to progress, the human body creates chemicals that can remove telomerase from aberrant methylation enzymes in cancer cells. The Chinese FDA has approved Cell Differentiation Agent-2 (CDA-2) for cancer therapy. It is a preparation of human metabolites from freshly collected urine. Differentiation Inducers (DIs), which target aberrant methylation enzymes' telomerase, and Differentiation Helper Inducers (DHIs), which are inhibitors of individual ternary methylation enzymes, are both efficient components of CDA-2. CDA-2 was found to be particularly efficient in the treatment of Myelodysplastic Syndrome (MDS), a disease caused by Cancer Stem Cells (CSCs). We have previously conducted substantial research on CDA-2 DHIs. We're presently concentrating on the CDA-2 DIs in order to create synthetic CDA for cancer prevention and therapy by targeting CSCs. Differential solvent extraction, gel filtering, ion exchange chromatography, TLC, and HPLC were used to purify DIs from CDA-2 solution. Mass spectroscopy was used to determine the mass of the purified active preparation. The Nitro Blue Tetrazolium (NBT) test of HL-60 cells was used to determine DI activity. CDA-2 DIs were mostly identified as acidic liposomal complexes that could be extracted with dichloromethane. Many of these were covalently attached to inactive carriers that were not soluble in dichloromethane but were soluble in alcohols. Pregnenolone has been found as a DHI of active liposomal complexes. The active DIs of CDA-2 were not related with UV absorption peaks of HPLC after dissociation from pregnenolone. Because acidic peptides of CDA-2 were previously found to be active DIs, we assumed that the active DIs might be acidic peptides produced from endogenous proteins. To investigate their DI actions, we synthesised pentapeptides comprising at least two acidic amino acid residues from the sequences of - and -hemoglobin. Although the actions of acidic pentapeptides of haemoglobin as DIs were not noteworthy, they did exist. Retinoic Acid (RA) and 12-O-TetradecanoylPhorbol-13-Acetate (TPA) are two well-known DIs that have significantly improved activity. Pyrvinium Pamoate (PP) was determined to be the best DHI, and triinosinate + tetrainosinate (I3 + I4) was found to be an acceptable DHI in this investigation. With effective DIs and DHIs on hand, we devised the following CDA formulations: CDA-MDS was RA(ED25)-5P-1(ED25)-I3 + I4(RI0.5)-PP(RI0.5)-sodium pregnenolone sulfate(RI0.5), CDA-CSC was RA(ED25)- TPA(ED25)-PP(RI0.5)-resveratrol(RI0.5)-curcumin(RI0.5), CDA-BT was TPA(2xED25)-PP( (RI0.5). On HL-60 cells, all of the CDA formulations mentioned yielded 100% NBT +. Finally, CDA formulations are the most effective at removing CSCs protected by drug resistance mechanisms. CSCs have a vital biological mission of wound healing. DIs and DHIs, wound healing metabolites and partners in the biological mission of CSCs, make up the majority of CDA formulations. DIs and DHIs are, of course, bearable to CSCs. CDA formulations can also cause cancer cells to undergo TD, which stops them from growing.

Author(s) Details

Ming C. Liau
CDA Therapeutics, Tustin, CA, USA.

Paul A. Fruehauf
CDA Therapeutics, Tustin, CA, USA.

Zhong-Hui Zheng
Division of Research and Development, Xinhua Pharmaceutical Co., Zibo, Shandong, China.

John P. Fruehauf
Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, CA, USA.

View Book :- https://stm.bookpi.org/CAPRD-V2/article/view/3959